Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for RVX
2.02
-0.04 (-1.94%)
Sep 4 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.92 - 2.05
52 week 0.41 - 3.13
Open 2.05
Vol / Avg. 36,865.00/44,851.00
Mkt cap 210.83M
P/E     -
Div/yield     -
EPS -0.28
Shares 105.08M
Beta 1.91
Inst. own     -
Sep 17, 2015
Resverlogix Corp at EBD Group BioPharm America - 12:00PM EDT - Add to calendar
Sep 10, 2015
Resverlogix Corp at Rodman & Renshaw Global Investment Conference - 10:25AM EDT - Add to calendar
  

Key stats and ratios

Q2 (Apr '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -377.26% -151.54%
Return on average equity - -
Employees 19 -
CDP Score - -

Address

300-4820 Richard Rd SW
CALGARY, AB T3E 6L1
Canada
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)

Website links

Description

Resverlogix Corp. is a clinical-stage cardiovascular company. The Company is developing small molecules that selectively inhibit Bromodomain and ExtraTerminal domain (BET) proteins. Its lead drug compound is RVX-208 (apabetalone). RVX-208 is a small molecule targeted for the treatment of atherosclerosis via the reduction of major adverse cardiovascular events (MACE), and also for treatment of diabetes mellitus (DM), chronic kidney disease (CKD) and Alzheimer's disease (AD). RVX-208 is an oral agent in the BET inhibitor class that targets bromodomain 2 (BD2) of BET protein4 (BRD4) by regulating gene activities. RVX-208 has anti-inflammatory effects, including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, complement, factors involved in atherosclerosis and vascular risk. The Company has initiated a Phase III clinical trial BETonMACE with RVX-208 for cardiovascular disease patients with DM and low high-density lipoprotein (HDL).

Officers and directors

Peter Johann Ph.D. Independent Chairman of the Board
Donald J. McCaffrey President, Chief Executive Officer, Secretary, Director
A. Brad Cann CA Chief Financial Officer
Jan O. Johansson M.D., Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Michael T. Sweeney M.D. Senior Vice President - Clinical Development
Norman Wong M.D. Chief Scientific Officer
Kelly B. McNeill Independent Director
Eldon R. Smith M.D. Independent Director
Age: 75
Kenneth J. Zuerblis Independent Director
Age: 56